进展性脑挫裂伤出血是影响颅脑创伤患者预后的一个重要因素。在前期一系列的研究中，我们发现体内FVII水平不仅与进展性脑挫裂伤出血的发生密切相关，给予重组FVIIa还可以防止进展性脑挫裂伤出血的发生。但重组FVIIa系统给药后体内半衰期短和血栓事件发生风险大的缺点限制了其在颅脑创伤患者中的应用。红细胞膜因具有天然体内长循环、生物相容性好、可包封大分子量蛋白质和可表面修饰等特点而被认为是最具应用前景的药物载体。为此，我们将以此为突破点，首先制作FVIIa纳米微粒并对其进行红细胞膜包封，构建出纳米红细胞膜-FVIIa微粒，以达到其良好的体内长循环减低药物用量。然后对纳米红细胞膜-FVIIa微粒用CREKA进行修饰，构建出纳米红细胞膜-CREKA-FVIIa凝血系统，使其可以靶向的作用于脑挫裂伤出血部位，提高药物的疗效，减低副作用。为FVIIa能够更有效的应用于进展性脑挫裂伤出血的救治提供实验基础。

Progressive cerebral contusion hemorrhage is an important factor affecting the prognosis of patients with traumatic brain injury. In a series of preliminary studies, we found that FVII activity was closely related with the occurrence of progressive cerebral contusion hemorrhage and the use of recombinant factor VIIa was effective for preventing the occurrence of progressive cerebral contusion hemorrhage. However, the short half-life and high thrombosis risk limit the application of recombinant factor VIIa in traumatic brain injury patients. The erythrocyte membrane is considered to be the most promising drug carriers，because it has the characteristic of natural long cycle, good biocompatibility, encapsulation of high molecular weight protein and modifiability in the cell surface. Therefore, we will take this as a breakthrough point. We firstly use erythrocyte membrane to encapsulate FVIIa nanoparticles in order to achieve the long cycle in vivo and to reduce drug dosage. Then, the erythrocyte membrane-FVIIa nanoparticles was modified with a fibrin-binding pentapeptide (cysteine – arginine – glutamic acid– lysine– alanine,CREKA) to build erythrocyte membrane-CREKA-FVIIa targeted coagulation system in order that it can target the brain contusion site, improve the drug efficacy and reduce the side effects, which provides the theoretical basis for the use of FVIIa in progressive cerebral contusion hemorrhage.